Wednesday, June 2, 2021

Part 1 Contextualizing the need for a framework toward scholarly integration of Medical education and research

 To put the current disintegration of Medical education and practice into context, we need to first understand individual patient requirements and societal requirements to gain further insights into medical practice and how it can be integrated with medical education. 


We share below an illustrative example from one of our online expert patients that we have published before here: https://pubmed.ncbi.nlm.nih.gov/19018905/


The layer of Individual patient experience

(Medical practice) : 


Patient’s voice – (in italics)

It all started in the summer of... when I

returned from a long weekend . . . it was

cool and rainy there.


I ate too many gravy coated potato fries,

drove home in damp clothes, and caught

what I thought was the flu.


It didn’t respond to my usual cure of lying on

the sofa and watching four rented videos.


In a few weeks I noticed some black and

blue marks on my arm and panicked when

I didn’t stop bleeding from a small cut.

My days became a struggle to continue life,

as I once knew it and understand why

my body was betraying me.


(Medical Education) A medical students related lecture notes although apparently distant  from the above patient context:


Physiology of Haemostasis

The cessation of bleeding from damaged

blood vessel. After vessel injury, process of

haemostasis takes place in two phases:

Primary:

1. Vessel wall contraction

2. Platelet aggregation & plugging of injured

area

Secondary:

3. Formation of an insoluble fibrin clot

because of activation of clotting system

What are the abnormalities of haemostasis

that may have caused abnormal bleeding

in this patient?

Haemorrhagic diseases can result from

abnormalities of:

Blood vessels

Platelets

Clotting systems

Diseases affecting the smaller blood vessels

& platelets produce the clinical picture of

purpura.

Integrating medical education and practice:


The practice passage above  begins an individual

clinical encounter with an audience (us) and we

notice that the initial queries generated

even by a patient are always something

like: 


Where is the problem? (a physician’s

morphologic diagnosis)


Why is the problem (a physician’s etiologic

diagnosis) 


and this is mostly answered by

pathophysiologic rationale that patients are

not expected to know (and may not

understand even through Internet

searches).

However, this is what physician’s are

expected to know as a result of their

training (and improve on with experience).

The most basic of these is the knowledge

of anatomy that takes time to change

unlike empirical evidence in medicine that

has proven to have a very short shelf life.


A physician by virtue of this basic knowledge

of macro- and microanatomy is able to

quickly grasp other information that keeps

adding to his lifelong day-to-day learning in

medicine.


It can often happen that what the physician had held as rote memorized facts (education) to apply to the current patient at hand (practice) may often fall short when it actually comes to deal with diagnostic and therapeutic uncertainty. 


Let's return to the same patient centered example to check the challenges around integrating therapeutic uncertainty 

Patient voice 2:

"The haematologist suggested prednisone,

the drug of choice. I was wary of the

side effects, but this seemed to be the

best option.


For three weeks I endured the brain fog,

sleepless nights, and anxiety, hoping the

drug would be a quick fix. It wasn’t.


There was only a slight rise in my platelet

count, then a fall. He then suggested IVIg."


Most physicians elect to not treat patients

unless their platelet count is below

50 000 L-1 or bleeding manifestations are

present.


Only 15%-25% of patients on steroids are

expected to have lasting remission;

The remainders have disease characterized by

frequent relapses and remissions.

Thiagarajan, P. (2006) Platelet disorders, E-medicine from web MD,

Web document last downloaded on August 16, 2007.


We enter the zone of empirical evidence that

tells us what intervention to choose for our

patient at hand utilizing population-based

data from collective experimentation.



The layer of Individual experience

Surviving and healing phase


Patient voice :


"The next round of IVIg was less successful in

raising my counts. The round after that had

almost no effect. I agreed to have my

spleen removed, hoping again for a quick

fix and to put an end to the endless round

of doctor appointments, hospitalizations

and the constant fear of bumping my head

and dying. Before I left for the hospital I

placed my will on my dresser."


Collective experience and its

conceptual layers


IV (Intravenous) IgG (Immunoglobulin G)

(0.8–1 g kg-1 for 2 d) can cause adverse

effects of IgG include fever, nausea,

vomiting, and, occasionally, renal failure.

Chronic ITP patients who fail to maintain

normal platelet count are eligible for Elective

Splenectomy. Splenectomy is effective

because it removes the major

site of destruction and the major source

of antiplatelet antibody synthesis.

Approximately 10%-20% of patients

who undergo splenectomy remain

thrombocytopenic and continue to have a

bleeding risk.


Patient voice :

My surgery was successful in that I survived,

my spleen was removed and the wound

eventually healed. However, it was not

successful in raising my platelet count.


Three weeks after the surgery I had as few

platelets as before the operation. Now I

was without a spleen bruised, and still on

the seizure meds.


Collective experience and its

conceptual layers:


A number of treatments have been

proposed for splenectomy and steroid

failures. Most of them are not based on placebo-

controlled studies, and evaluating the

efficacy of these treatments in a disease

associated with spontaneous remissions

and relapse is difficult.


Other treatment regimes:

High dose corticosteroids (iv)

High dose iv Ig

Rituximab

iv Anti-RhD

Danazol, colchicine

Vinca alkaloids

Immunosuppresive drugs: Azathioprine,

Cyclosporine, Dapsone


Patient Voice 


My hematologist recommended Danazol...

No luck . . . Colchicine failed too. We even

tried another course of IVIg hoping that my

body would respond to it differently now

that I didn’t have a spleen. It responded

differently all right. I was hospitalized

following one of the treatments for a

nosebleed that didn’t stop. I went to an ITP

specialist in . . . and he berated my local

hematologist for not putting me in the

hospital.


I reluctantly agreed to a course of vincristine

(chemotherapy) followed by a series of Prosorba.

A blood cleansing treatments. They sneaked

in more of the dreaded prednisone.

At the same time I also took up alternative wellness techniques that gradually began to enrich my life. I returned to work at the end of March, part time wearing a wig, on the day that my short-term disability insurance ended. My counts were still low, but I was thrilled to have parts of my life back. In a few weeks, I began full time work again.

The above expert patient has subsequently published another paper with our team members where she elaborated on her cure and the integration of multidisciplinary interventions that was brought about to effect it. She subsequently utilized the power of online integration to provide a voice to similar stories from many patients around the world. 


Reference link:

https://www.irma-international.org/article/caught-middle-divide-between-conventional/52621/



Please click on the link below to get back to the first layer of the chapter:



No comments:

Post a Comment